Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nb2-MDTCS
- Development stage
- Preclinical
- Lead developer
- Cardiovascular Research Institute Maastricht
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Nb2-MDTCS is an experimental recombinant fusion protein designed to investigate the role of ADAMTS13 in glycoprotein VI (GPVI)-dependent platelet activation. It consists of the inhibitory anti-GPVI single-domain antibody (nanobody) Nb2 fused to the active MDTCS (Metalloprotease, Disintegrin, Thrombospondin-1, Cysteine-rich, and Spacer) domains of the multidomain metalloprotease ADAMTS13. While monomeric Nb2 typically suppresses GPVI-dependent platelet activation, the Nb2-MDTCS construct binds to von Willebrand factor (VWF) multimers via its MDTCS domains, leading to the clustering and activation of GPVI receptors on platelets. This fusion protein retains the proteolytic activity of ADAMTS13 toward VWF and serves as a valuable research tool to explore GPVI-targeted modulation of platelet activation and receptor cross-talk in arterial thrombosis.
- Other names
- Nb2-MDTCS constructNb-2-MDTCS constructNb 2-MDTCS constructNb2-MDTCS fusion proteinNb-2-MDTCS fusion proteinNb 2-MDTCS fusion protein
02
Targets
GPVI (Platelet glycoprotein VI)BB-031 (Von Willebrand factor)
Beyond the preview
Go deeper on Nb2-MDTCS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nb2-MDTCS.